PR85035

Caprion-HistoGeneX and Viroclinics-DDL announce a strategic partnership to offer integrated, complementary services to advance infectious disease research and COVID-19 therapeutic development

MONTREAL and ROTTERDAM, Netherlands, Aug. 7, 2020 /PRNewswire=KYODO JBN/ --

-- Caprion-HistoGeneX, a specialized CRO providing immunology, proteomics,

histopathology and genomics services, and Viroclinics-DDL, a provider of

preclinical and clinical trial services for vaccine, antiviral, and diagnostic

development, are pleased to announce a new partnership that will offer global,

integrated services to support discovery and development of vaccines and

antiviral therapies.

Caprion-HistoGeneX and Viroclinics-DDL announced today a new strategic

partnership to expand their global capabilities addressing the emerging needs

for therapeutic and prophylactic solutions to target infectious diseases

including COVID-19. This partnership brings together the leadership of two

prominent contract research organizations serving the pharmaceutical and

biotechnology community with specialized assays and technologies relevant to

clinical and preclinical studies aimed at developing vaccines and other

therapies for infectious diseases.

Logo –

https://mma.prnewswire.com/media/1224618/Caprion_Biosciences_Caprion_HistoGeneX_and_Viroclinics_DDL_annou.jpg

Logo -

https://mma.prnewswire.com/media/1224779/Caprion_Biosciences_Caprion_HistoGeneX_and_Viroclinics_DDL_annou.jpg

By combining their respective expertise, the two companies offer a full suite

of specialized services to support vaccine and antiviral studies along with a

broad global presence, including sites in The Netherlands, Canada, USA,

Belgium, UK, Australia, and China.

"We are excited to partner with Caprion-HistoGeneX and combine the unique

strengths of our companies to deliver first class contract research services to

our customers developing innovative modalities to combat infectious diseases."

said Davide Molho DVM, the new CEO of Viroclinics-DDL.

The partnership allows for a seamless, integrated service experience for

customers worldwide, with a broad service offering covering all stages of

vaccine and antiviral development, ranging from preclinical and in-vitro

research models to the deployment of custom-developed and off-the-shelf

functional assays for monitoring vaccine efficacy. In addition to leveraging a

broad selection of specialized platforms such as viral neutralization, flow

cytometry, ELISpot and immuno-assays, the partnership will also provide access

to an extended global network of clinical sample processing facilities across

North America, South America, Europe, Africa and Asia, along with operational

and logistical services including sample management and sampling kits.

"With our complementary competencies, we are able to fulfill the R&D and

clinical outsourcing needs of the market. In the wake of the current COVID-19

pandemic, we believe that this joint initiative will bring vaccine and

antiviral testing to the next level." said Martin LeBlanc, CEO of

Caprion-HistoGeneX.

About Caprion Biosciences Inc.

Caprion - HistoGeneX is a leading provider of specialized precision medicine

services to the biopharmaceutical industry including flow and mass cytometry

immune monitoring, quantitative mass spectrometry, molecular profiling, as well

as quantitative immunohistochemistry. Leveraging its integrated platforms,

Caprion-HistoGeneX supports the entire drug development cycle, from discovery

to clinical trials. The company operates globally with laboratories located in

Canada, USA, Belgium, UK, Australia, and China.

For more information: www.caprion.com and www.histogenex.com

About Viroclinics-DDL

Viroclinics-DDL is a global leading virology contract research organization,

serving the biopharmaceutical community with a broad range of preclinical

research, clinical diagnostic, assay development and clinical trial logistic

services. Viroclinics' extensive experience with clinical and preclinical

studies for viruses, including its specialty in respiratory viruses, puts the

company at the forefront in supporting the development of vaccines, antibodies

and antiviral compounds targeting viral infectious diseases. Our in-house state

of the art preclinical and clinical BSL-2 and BSL-3 laboratories allow for

complex experiments with highly pathogenic organisms. Viroclinics is based in

Rotterdam, Rijswijk, Schaijk, (The Netherlands) and employs more than 270

well-trained, dedicated scientists and technical experts. For more information:

www.viroclinics.com and www.ddl.nl

Media Contact: Viroclinics-DDL, Sander Verkerk, Manager Marketing &

Communication, Viroclinics-DDL, marketing@viroclinics.com; Media Contact:

Caprion Biosciences Inc., Guylaine Galipeau, Global Marketing Director, Caprion

Biosciences Inc., info@caprion.com

Source - Caprion Biosciences